Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs

被引:15
作者
Johannessen, SI [1 ]
机构
[1] Natl Ctr Epilepsy, N-1306 Sandvika, Norway
关键词
therapeutic drug monitoring; new antiepileptic drugs; serum concentrations;
D O I
10.1097/01.ftd.0000179852.39717.3e
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The aim of this brief communication is to update our recent review on therapeutic drug monitoring (TDM) of the newer antiepileptic drugs (AEDs). The potential value of TDM is discussed in relation to their mode of action and their pharmacokinetic properties. Data on the relationships between serum concentrations and clinical efficacy are limited, and few studies have been designed primarily to study these relationships. As yet there,are no generally accepted target ranges for any of the new AEDs. For most drugs a wide range in serum concentration is associated with clinical efficacy, and there is a considerable overlap in serum concentrations related to toxicity and lack of clinical efficacy. Although the available documentation is clearly insufficient, the pharmacological proper-ties of some of the drugs suggest that they may be suitable candidates for TDM. The primary role of TDM for both the newer and established AEDs is to identify an individual's optimum concentration and thus establish a reference value in that patient.
引用
收藏
页码:710 / 713
页数:4
相关论文
共 22 条
[1]  
Adin J, 2004, THER DRUG MONIT, V26, P251
[2]   10-hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio - Influence of age and concomitant antiepileptic drugs [J].
Armijo, JA ;
Vega-Gil, N ;
Shushtarian, M ;
Adin, J ;
Herranz, JL .
THERAPEUTIC DRUG MONITORING, 2005, 27 (02) :199-204
[3]   Association between patient age and gabapentin serum concentration-to-dose ratio -: A preliminary multivariate analysis [J].
Armijo, JA ;
Pena, MA ;
Adín, J ;
Vega-Gil, N .
THERAPEUTIC DRUG MONITORING, 2004, 26 (06) :633-637
[4]   Topiramate pharmacokinetics in children and adults with epilepsy - A case-matched comparison based on therapeutic drug monitoring data [J].
Battino, D ;
Croci, D ;
Rossini, A ;
Messina, S ;
Mamoli, D ;
Perucca, E .
CLINICAL PHARMACOKINETICS, 2005, 44 (04) :407-416
[5]   Pregabalin pharmacology and its relevance to clinical practice [J].
Ben-Menachem, E .
EPILEPSIA, 2004, 45 :13-18
[6]   Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) [J].
Bialer, M ;
Johannessen, SI ;
Kupferberg, HJ ;
Levy, RH ;
Perucca, E ;
Tomson, T .
EPILEPSY RESEARCH, 2004, 61 (1-3) :1-48
[7]   Pharmacokinetic interactions of topiramate [J].
Bialer, M ;
Doose, DR ;
Murthy, B ;
Curtin, C ;
Wang, SS ;
Twyman, RE ;
Schwabe, S .
CLINICAL PHARMACOKINETICS, 2004, 43 (12) :763-780
[8]   Levetiracetam therapeutic monitoring in patients with epilepsy - Effect of concomitant antiepileptic drugs [J].
Contin, M ;
Albani, FA ;
Riva, R ;
Baruzzi, A .
THERAPEUTIC DRUG MONITORING, 2004, 26 (04) :375-379
[9]   Age and antiepileptic drugs influence topiramate plasma levels in children [J].
Dahlin, MG ;
Öhman, IK .
PEDIATRIC NEUROLOGY, 2004, 31 (04) :248-253
[10]   Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response [J].
Ferrari, AR ;
Guerrini, R ;
Gatti, G ;
Alessandrì, MG ;
Bonanni, P ;
Perucca, E .
THERAPEUTIC DRUG MONITORING, 2003, 25 (06) :700-708